On May 25, 2021, Dr. David Heimansohn successfully performed the first surgical implantation of biopolymer Tria™ heart valve in a patient with mitral valve disease at Ascension St. Vincent Hospital, Indianapolis, IN.
Foldax’s Tria valve is fabricated with a polymeric, silicone-rich polyurethane material intended to resist calcification, improve valve durability, and, most importantly, avoid the need for lifelong anticoagulation.
You are here:
Foldax Announces Successful First Human Use of Tria Biopolymer Mitral Heart Valve
Submitted by: Wei-Guo Ma
Source: Foldax news and events
Keywords:
Author(s): Foldax Inc
